Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 3/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.38 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.38 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | PDE4A | P27815 | 6/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | PDE5A | O76074 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1157399 | 0.91 | PDE4D (0.44) | PDE4APDE4DPDE4BPDE4CPDE5A | |
| SCHEMBL1157395 | 0.90 | PDE4A (0.46) | FGFR3FGFR1FGFR2FGFR4KDR | |
| SCHEMBL1157638 | 0.89 | PDE4B (0.39) | FGFR3FGFR1FGFR2FGFR4KDR | |
| SCHEMBL1157864 | 0.86 | PDE4D (0.42) | PDE4APDE4DPDE4BPDE4CPDE5A | |
| SCHEMBL1157336 | 0.85 | PDE4A (0.46) | FGFR3FGFR1FGFR2FGFR4KDR | |
| SCHEMBL1157370 | 0.81 | PDE4D (0.40) | FGFR3FGFR1FGFR2FGFR4KDR | |
| SCHEMBL4200954 | 0.80 | PDE4A (0.44) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL1157549 | 0.80 | PDE4D (0.34) | FGFR3FGFR1FGFR2FGFR4KDR | |
| SCHEMBL2905397 | 0.79 | PDE4A (0.34) | FGFR3FGFR1FGFR2FGFR4KDR | |
| SCHEMBL4202620 | 0.79 | PDE4A (0.37) | FGFR3FGFR1FGFR2FGFR4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046146-A9 | Phosphodiesterase 4 inhibitors | SCHUMACHER RICHARD A | 2011-02-24 | — | — | US | disclosed |
| US-20090048255-A1 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS | SCHUMACHER RICHARD A | 2009-02-19 | — | — | US | disclosed |
| US-7205320-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. (US) | 2007-04-17 | — | — | US | disclosed |
| US-20070078139-A1 | Phosphodiesterase 4 inhibitors | SCHUMACHER RICHARD A | 2007-04-05 | — | — | US | disclosed |
| US-20040230072-A1 | Phosphodiesterase 4 inhibitors | SCHUMACHER RICHARD A (US) | 2004-11-18 | — | — | US | disclosed |
| US-6699890-B2 | N-SUBSTITUTED DIETHER ANILINE AND DIETHER DIPHENYLAMINE DERIVATIVES | MEMORY PHARMACEUTICALS CORP. | 2004-03-02 | — | — | US | disclosed |
| EP-1353907-A2 | PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceutical Corporation (US) | 2003-10-22 | — | — | EP | disclosed |
| US-20030149052-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. | 2003-08-07 | — | — | US | disclosed |
| US-20020151566-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. (US) | 2002-10-17 | — | — | US | disclosed |
| WO-2002074726-A2 | ANILINE DERIVATIVES USEFUL AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149052-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE3A | FGFR3 2661/4885FGFR1 2726/4885FGFR2 3991/4885 |
| US-20020151566-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE3A | FGFR3 2661/4885FGFR1 2726/4885FGFR2 3991/4885 |
| US-20040230072-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE3A | FGFR3 2661/4885FGFR1 2726/4885FGFR2 3991/4885 |
| US-20110046146-A9 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE3B | FGFR3 2036/4885FGFR1 2291/4885FGFR2 3767/4885 |
| US-20070078139-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE3B | FGFR3 2036/4885FGFR1 2291/4885FGFR2 3767/4885 |
| US-20090048255-A1 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS | PDE4A, PDE4B, PDE3A | FGFR3 2210/4885FGFR1 2420/4885FGFR2 3785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.